Advanced Influenza Technologies (AIT) holds the license for a DNA-based Influenza vaccine candidate developed at the University of Massachusetts Medical School.
“Years of effort have been expended developing DNA-based vaccine technology at UMass Medical School,” said Dr James McNamara, executive director of the university’s office of technology management. “We hope to see that work successfully commercialized, through this licensing agreement so that the public may benefit.”
“Utek is pleased to consummate this technology transfer with CytoDyn, Inc. and we look forward to continuing our efforts to identify additional technology acquisition opportunities for its consideration,” said Dr Jeffrey Bleil, chief technology officer of Utek Corporation.